Eleven Biotherapeutics Inc (NASDAQ:EBIO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Eleven Biotherapeutics, Inc. is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal preclinical product candidate consist of EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis, EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis. Eleven Biotherapeutics, Inc. is based in Cambridge, United States. “

Shares of Eleven Biotherapeutics (NASDAQ:EBIO) traded down 3.53% during mid-day trading on Tuesday, reaching $1.64. 221,794 shares of the company traded hands. The company has a market capitalization of $25.24 million, a P/E ratio of 10.86 and a beta of 3.69. The stock’s 50-day moving average is $1.94 and its 200-day moving average is $2.07. Eleven Biotherapeutics has a 52 week low of $1.03 and a 52 week high of $5.97.

Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.25) EPS for the quarter. The firm had revenue of $0.43 million for the quarter. Eleven Biotherapeutics had a negative return on equity of 25.00% and a negative net margin of 16.51%. On average, equities analysts predict that Eleven Biotherapeutics will post ($1.75) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/05/16/zacks-investment-research-upgrades-eleven-biotherapeutics-inc-ebio-to-hold.html.

Large investors have recently modified their holdings of the company. Oxford Asset Management purchased a new stake in shares of Eleven Biotherapeutics during the fourth quarter worth approximately $343,000. Vanguard Group Inc. increased its stake in shares of Eleven Biotherapeutics by 45.1% in the first quarter. Vanguard Group Inc. now owns 175,850 shares of the biopharmaceutical company’s stock worth $386,000 after buying an additional 54,694 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Eleven Biotherapeutics by 0.6% in the first quarter. Geode Capital Management LLC now owns 47,187 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 300 shares during the period. Institutional investors and hedge funds own 24.75% of the company’s stock.

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

5 Day Chart for NASDAQ:EBIO

Get a free copy of the Zacks research report on Eleven Biotherapeutics (EBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eleven Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.